admin – Page 4282 – Get News Story

Esophageal Squamous Cell Carcinoma FDA Approvals, Clinical Trials, Pipeline Insights and Companies | DelveInsight

DelveInsight’s, “Esophageal Squamous Cell Carcinoma Pipeline Insight” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Esophageal Squamous Cell Carcinoma pipeline landscape. It covers the Esophageal Squamous Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Esophageal Squamous Cell Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Esophageal Squamous Cell Carcinoma Treatment Landscape. Click here to read more @ Esophageal Squamous Cell Carcinoma Pipeline Outlook

Key Takeaways from the Esophageal Squamous Cell Carcinoma Pipeline Report

In January 2025:- Hoffmann-La Roche– The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo in participants with unresectable esophageal squamous cell carcinoma (or those who are unable or unwilling to undergo surgery) and whose cancers have not progressed following definitive concurrent chemoradiotherapy (dCRT). Participants will be randomized in a 1:1:1 ratio to receive either tiragolumab plus atezolizumab (Arm A), tiragolumab matching placebo plus atezolizumab (Arm B), or double placebo (Arm C).
In January 2025:- Merck Sharp & Dohme LLC:- This is a phase I/II multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of investigational agents with pembrolizumab, plus chemotherapy or lenvatinib, for the treatment of participants with advanced esophageal cancer who have failed 1 prior line of therapy and have not been previously exposed to programmed cell death 1 protein (PD-1)/ programmed cell death ligand 1 (PD-L1) based treatment.
In January 2025:- Suzhou Suncadia Biopharmaceuticals Co., Ltd.:- Objective response rate (ORR) was evaluated to evaluate the efficacy of SHR-8068 combined with adebrelimab and platinum-containing chemotherapy in first-line treatment of advanced gastric and esophageal cancer.
DelveInsight’s Esophageal Squamous Cell Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Esophageal Squamous Cell Carcinoma treatment.
The leading Esophageal Squamous Cell Carcinoma Companies such as BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Servier, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Eli Lilly and Company, Exelixis, Symphogen A/S, Bayer, Eisai Inc., and others.
Promising Esophageal Squamous Cell Carcinoma Therapies such as Camrelizumab, SI-B001, Irinotecan, Paclitaxel, Cisplatin, JMT101, and others.

Discover groundbreaking developments in Esophageal Squamous Cell Carcinoma therapies! Gain in-depth knowledge of key Esophageal Squamous Cell Carcinoma clinical trials, emerging drugs, and market opportunities @ Esophageal Squamous Cell Carcinoma Clinical Trials Assessment

Esophageal Squamous Cell Carcinoma Emerging Drugs Profile

Tislelizumab: BeiGene

Tislelizumab (BGB-A317) is a humanized IgG4 anti–PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is the first drug candidate produced from BeiGene’s immuno-oncology biologic program, and we believe it could serve as a key element of our immuno-oncology combination platform. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. Currently, it is in Phase III stage of clinical trial evaluation to treat Esophageal Squamous Cell Carcinoma.

Serplulimab: Shanghai Henlius Biotech

Serplulimab (novel anti-PD-1 mAb) is the first innovative monoclonal antibody (mAb) developed by Henlius. Shanghai Henlius Biotech, announced that the phase 3 clinical study ASTRUM-007 of HANSIZHUANG (serplulimab) independently developed by the company in combination with chemotherapy as a first-line treatment for patients with locally advanced/metastatic esophageal squamous cell carcinoma (ESCC), met the co-primary endpoints of progression-free survival (PFS) and overall survival (OS) in a planned interim analysis, evaluated by the Independent Data Monitoring Committee (IDMC).

Stay informed about the Esophageal Squamous Cell Carcinoma pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Esophageal Squamous Cell Carcinoma Unmet Needs

Esophageal Squamous Cell Carcinoma Companies

BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Servier, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Eli Lilly and Company, Exelixis, Symphogen A/S, Bayer, Eisai Inc., and others.

Esophageal Squamous Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous
NA
Oral
Oral/intranasal/subcutaneous
Parenteral
Subcutaneous

Esophageal Squamous Cell Carcinoma Products have been categorized under various Molecule types such as

Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine

Transform your understanding of the Esophageal Squamous Cell Carcinoma Pipeline! See the latest progress in drug development and clinical research @ Esophageal Squamous Cell Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Esophageal Squamous Cell Carcinoma Pipeline Report

Coverage- Global
Esophageal Squamous Cell Carcinoma Companies- BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Servier, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Eli Lilly and Company, Exelixis, Symphogen A/S, Bayer, Eisai Inc., and others.
Esophageal Squamous Cell Carcinoma Therapies- Camrelizumab, SI-B001, Irinotecan, Paclitaxel, Cisplatin, JMT101, and others.
Esophageal Squamous Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Esophageal Squamous Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Oncology Research–Access the Full Esophageal Squamous Cell Carcinoma Pipeline Analysis Today! @ Esophageal Squamous Cell Carcinoma Drugs and Companies

Table of Content

1. Introduction

2. Executive Summary

3. Esophageal Squamous Cell Carcinoma: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Esophageal Squamous Cell Carcinoma – DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

8. Tislelizumab: BeiGene

9. Drug profiles in the detailed report…..

10. Mid Stage Products (Phase II)

11. RAPA-201: Rapa Therapeutics

12. Drug profiles in the detailed report…..

13. Early Stage Products (Phase I)

14. SGN-B6A: Seagen

15. Drug profiles in the detailed report…..

16. Preclinical and Discovery Stage Products

17. Drug name: Company name

18. Drug profiles in the detailed report…..

19. Inactive Products

20. Esophageal Squamous Cell Carcinoma Key Companies

21. Esophageal Squamous Cell Carcinoma Key Products

22. Esophageal Squamous Cell Carcinoma- Unmet Needs

23. Esophageal Squamous Cell Carcinoma- Market Drivers and Barriers

24. Esophageal Squamous Cell Carcinoma- Future Perspectives and Conclusion

25. Esophageal Squamous Cell Carcinoma Analyst Views

26. Esophageal Squamous Cell Carcinoma Key Companies

27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/bone-growth-stimulators-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Esophageal Squamous Cell Carcinoma FDA Approvals, Clinical Trials, Pipeline Insights and Companies | DelveInsight

Fuel Additives Market Trend, Explosive Growth Opportunity, Forecast to 2029 | Expert Review

“Browse 378 market data Tables and 54 Figures spread through 287 Pages and in-depth TOC on “Fuel Additives Market””

The increasing demand for fuel efficiency is one of the main factors propelling the fuel additives market. Fuel additives are chemical substances that are used to improve the efficiency and performance of fuels in internal combustion engines.

In terms of value, the fuel additives market is estimated to grow from USD 6.7 billion in 2024 to USD 8.0 billion by 2029, at a CAGR of 3.6%. The increasing demand for fuel efficiency is one of the main factors propelling the fuel additives market. Fuel additives are chemical substances that are used to improve the efficiency and performance of fuels in internal combustion engines. They function by enhancing various qualities of fuels, such as its combustion characteristics, and by addressing problems like engine deposits, friction, and corrosion that can lower fuel efficiency. Thus, fuel additives are crucial in the quest to optimize consumption of fuel, which is being driven by various reasons that impact both consumers and industry.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=723

The automotive industry is undergoing substantial change due to the growing awareness of vehicle maintenance among the customers, and fuel additives are crucial in this regard. Fuel additives help to improve the overall combustion process along with maintaining the engine clean. The production of toxic pollutants, a reduction in power output, and decrease in fuel efficiency may arise from incomplete combustion. Certain fuel additives increase the fuel’s combustion properties, ensuring that the engine operates more effectively. Examples of these additives include, cetane improvers for diesel engines and octane improvers for gasoline engines. These factors are likely to drive the fuel additives market as an crucial part of vehicle maintenance.

Fuel Additives Companies

The key players profiled in the report include Innospec Inc. (US), Infineum International Limited (UK), Chevron Oronite Company LLC (US), Afton Chemical Corporation (US), BASF SE (Germany), The Lubrizol Corporation (US), Evonik Industries AG (Germany), LANXESS AG (Germany), Dorf Ketal Chemicals LLC (India), and Clariant AG (Switzerland). These players have adopted various growth strategies to strengthen their position in the market. These include introducing new technologies, expansions, and product launches to acquire larger market shares.

Innospec Inc. is one of the leading manufacturers of fuel additives. It is international specialty chemicals company that operates through three business segments, namely, performance chemicals, fuel specialties, and oilfield services. Their product portfolio includes fuel additives, oilfield chemicals, personal care, alongside household and industrial products. The company offers fuel additives through fuel specialties segment. It maintains a strong geographic presence, with operations and customers in North America, South America, Middle East & Africa, Europe, and Asia Pacific. Innospec Inc. has industry-leading customer service and technical support, helping them to establish strong, long-term relationships with its clients. Their significant presence in the fuel additives market can be attributed to their specializations in the field, investing heavily in R&D to provide cutting-edge solutions to a variety of challenges.

Get a Sample Copy of This Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=723

Infineum International Limited is a global leader in the formulation, manufacturing, and marketing of petroleum additives for lubricants and fuels. The company has a strong emphasis on innovation and sustainability. Infineum International Limited develops advanced additives that meet stringent environmental regulations and performance standards enforced by environmental organizations. This company’s product portfolio is oriented in accordance with stringent consumer demands on modern engines: increased fuel efficiency, lower emissions, and more engine durability. Their global network includes manufacturing facilities, research and technology centers, and customer support offices, ensuring comprehensive service to a diverse customer base. Its strategic partnerships and collaborations with leading automotive and energy companies enable Infineum to stay at the forefront of industry trends and technological advancements.

Lubricity Improvers segment is projected to register the highest CAGR, in terms of value, of the global fuel additives market during the forecast period.

Lubricity improvers segment is the fastest growing segment in the fuel additives market during the forecast period. The key objective of these additives is to improve the lubricating qualities of the fuel, offering adequate safety against wear and tear for vital engine parts including fuel injectors and pumps. With the world moving towards cleaner, low-sulfur diesel fuels, the need for these additives has increased. Diesel engines are naturally lubricated to some extent by the sulfur compounds in the fuel. However, the natural lubricity of diesel has diminished due to stricter regulations, with the usage of minimum to zero level of sulfur in some regions. This factor has necessitated the growing use of lubricity improvers.

Gasoline is estimated to be the second-largest application of fuel additives market, in terms of value, during the forecast period.

The gasoline segment is estimated to be the second-largest application in the fuel additives market, in terms of value, during the forecast period. Gasoline is still the primary source for a majority of the world’s vehicle fleet, especially in regions like Europe, North America and Asia Pacific, despite the increasing popularity of diesel engines and the slow transition to electric vehicles. Thus, the gasoline segment holds a significant share of the fuel additives the market, largely due to the sheer volume of gasoline consumed worldwide.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=723

Middle East & Africa is projected to register the second highest CAGR, in terms of value, during the forecast period in the fuel additives market.

Middle East & Africa is projected to register the second highest CAGR in the fuel additives market, in terms of value, during forecast period due to several factors. The rapid urbanization and economic development in the MEA countries owing to their extensive infrastructural development is one of the primary drivers of the high growth rate of fuel additives market. The need for fuel additives rises as these nations develop their industrial bases, make investments in transportation infrastructure, and support non-oil industries. Fuel additives play a crucial role in bolstering these rapidly growing sectors by improving the performance and efficiency of fuels, ensuring enhanced engine performance, minimized emissions, and optimal fuel usage overall.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/fuel-additives-market-723.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Fuel Additives Market Trend, Explosive Growth Opportunity, Forecast to 2029 | Expert Review

Hemophilia A FDA Approvals, Clinical Trials, Pipeline Insights, Drugs and Companies | DelveInsight

DelveInsight’s, “Hemophilia A Pipeline Insight” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Hemophilia A pipeline landscape. It covers the Hemophilia A pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia A therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Hemophilia A Treatment Landscape. Click here to read more @ Hemophilia A Pipeline Outlook

Key Takeaways from the Hemophilia A Pipeline Report

In January 2025:- CSL Behring:- A Phase 3, Open-label, Multicenter, Pharmacokinetics, Efficacy, and Safety Study of a Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Previously Treated Patients (PTPs) With Hemophilia A. For bridging the available global clinical data of rVIII-SingleChain, with the Chinese population, the aim of this study in China is to investigate the pharmacokinetics (PK) of rVIII-SingleChain after an initial and repeat dose and to assess efficacy and safety during 2 to 3 times weekly prophylaxis treatment with rVIII-SingleChain in male Chinese PTPs with severe hemophilia A (FVIII activity less than [<] 1%).
In January 2025:- Octapharma:-Female patients with mild to moderate haemophilia A will often need FVIII concentrates to provide haemostatic cover during major surgery. This prospective, open-label, non-controlled, single-arm, multinational, multicentre study aims to evaluate the overall perioperative haemostatic efficacy of Nuwiq in women/girls over 12 with haemophilia A undergoing major surgery requiring FVIII treatment.
In January 2025:- Bayer:- A Phase 1/2 Open-label Safety and Dose-finding Study of BAY2599023 (DTX201), an Adeno-associated Virus (AAV) hu37-mediated Gene Transfer of B-domain Deleted Human Factor VIII, in Adults With Severe Hemophilia A. By replacing the defective gene with a healthy copy the human body may produce clotting factor on its own. Hemophilia A is a bleeding disorder in which the human body does not have enough clotting factor VIII, a protein that controls bleeding. Researcher want to find the optimal dose of BAY 2599023 (DTX201) so that the body may produce enough clotting factor on its own.
DelveInsight’s Hemophilia A pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Hemophilia A treatment.
The leading Hemophilia A Companies such as Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd., Bayer, Ultragenix Pharmaceutical, Spark Therapeutics, Octapharma, ApcinteX Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Expression Therapeutics LLC, CSL Behring, and others.
Promising Hemophilia A Pipeline Therapies such as Emicizumab, rFVIIa, aPCC, BAX 888, OBIZUR, BIIB031 (rFVIIIFc), Recombinant Human Coagulation FVIII, and others.

Discover groundbreaking developments in Hemophilia A therapies! Gain in-depth knowledge of key Hemophilia A clinical trials, emerging drugs, and market opportunities @ Hemophilia A Clinical Trials Assessment

Hemophilia A Emerging Drugs Profile

AGN-193408: Allergan

Allergan is conducting a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-group (Cohort 2) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension. It is an implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix.

OCTA101: Octapharma

Octapharma is evaluating OCTA101 (a human-cl rhFVIII and recombinant human von Willebrand Factor fragment dimer) under a Phase 1/2 study, which will be a dose escalation study in adults in 5 cohorts, with the main purpose to assess the safety of subcutaneous injection of OCTA101 (in previously treated adult patients with severe hemophilia A. The study also aims to assess the pharmacokinetics (PK) characteristics, dose proportionality, and subcutaneous bioavailability of OCTA101 compared with intravenous administration of Nuwiq (Human-cl rh FVIII), in order to define the prophylactic treatment (dose and injection interval) that would result in protective trough levels of FVIII:C for future Phase 3 studies. By Data Monitoring Committee recommendation, patients enrolled in cohorts 1, 2 and 3 will proceed to 3-month prophylactic treatment to receive daily dosing of OCTA101 for 3 months.

Valoctocogene roxaparvovec: BioMarin Pharmaceuticals

Valoctocogene roxaparvovec, is an investigational gene therapy in clinical trials for the treatment of Hemophilia A and has not been determined to be safe or effective. Valoctocogene roxaparvovec is administered as a single infusion. The ongoing clinical trials will determine if the new gene will enable the body to produce factor VIII. Following infusion, clinical trial subjects are being evaluated to determine the safety profile, changes in Factor VIII activity levels, changes in factor replacement usage, changes in reported bleeds requiring factor replacement, and quality of life measures, among other endpoints.

Stay informed about the Hemophilia A pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Hemophilia A Unmet Needs

Hemophilia A Companies

Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd., Bayer, Ultragenix Pharmaceutical, Spark Therapeutics, Octapharma, ApcinteX Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Expression Therapeutics LLC, CSL Behring, and others.

Hemophilia A pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Molecule Type

Hemophilia A Products have been categorized under various Molecule types such as

Small molecules
Gene Therapies
Bispecific antibodies
Recombinant proteins
Fusion Proteins
Coagulants
Blood coagulation factor replacements

Transform your understanding of the Hemophilia A Pipeline! See the latest progress in drug development and clinical research @ Hemophilia A Market Drivers and Barriers, and Future Perspectives

Scope of the Hemophilia A Pipeline Report

Coverage- Global
Hemophilia A Companies- Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd., Bayer, Ultragenix pharmaceutical, Spark Therapeutics, Octapharma, ApcinteX Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Expression Therapeutics LLC, CSL Behring, and others.
Hemophilia A Pipeline Therapies- Emicizumab, rFVIIa, aPCC, BAX 888, OBIZUR, BIIB031 (rFVIIIFc), Recombinant Human Coagulation FVIII, and others.
Hemophilia A Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Hemophilia A Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Genetic Disorders Research–Access the Full Hemophilia A Pipeline Analysis Today! @ Hemophilia A Drugs and Companies

Table of Content

1. Introduction

2. Executive Summary

3. Hemophilia A: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Hemophilia A – DelveInsight’s Analytical Perspective

7. In-depth Commercial Assessment

8. Hemophilia A Collaboration Deals

9. Late Stage Products (Pre-registration)

10. Valoctocogene roxaparvovec: BioMarin Pharmaceutical

11. Late Stage Products (Phase III)

12. Giroctocogene fitelparvovec: Pfizer/ Sangamo Therapeutics

13. Mid Stage Products (Phase II)

14. NNC0365-3769 A (Mim8): Novo Nordisk A/S

15. Early Stage Products (Phase I/II)

16. BAX 888: Baxalta / Shire

17. BAY2599023: Bayer / Ultragenix pharmaceutical

18. Early Stage Products (Phase I)

19. Gene therapy: Expression Therapeutics, LLC

20. Drug profiles in the detailed report…..

21. Hemophilia A- Market Drivers and Barriers

22. Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hemophilia A FDA Approvals, Clinical Trials, Pipeline Insights, Drugs and Companies | DelveInsight

Milestone IP Law Firm: Driving Global Growth for High-Tech Companies

Milestone IP Law Firm, a leading provider of specialized intellectual property (IP) services in IT, software, and artificial intelligence (AI), is empowering domestic high-tech companies to thrive on the global stage.

Core Services:

– Advanced Technology Patent Filing: Comprehensive support for patent applications and examinations in critical fields, including electrical engineering, IT, software, and artificial intelligence.

– Global IP Portfolio Development: Tailored IP strategies and global portfolio creation to facilitate entry into international markets.

– Government-Supported Programs: Assistance in leveraging programs such as voucher schemes to reduce costs for startups and small businesses filing overseas patents, along with consulting services for global market expansion.

Milestone IP Law Firm has been widely recognized for its role in driving the growth of high-tech companies. By providing tailored IP strategies, the firm has helped numerous clients succeed in competitive international markets. One notable example is AI-focused startup A Company, which secured strategic patents in the U.S. and Europe through Milestone’s expert guidance. These patents enabled A Company to establish partnerships with leading global corporations, significantly enhancing its market position and growth prospects.

The firm’s market-driven approach has resonated strongly with its clients. “Milestone’s expertise and proactive strategies were instrumental in helping us navigate complex global IP landscapes,” said the CEO of A Company. “Their support has been vital to our international expansion and innovation leadership.”

“In the era of the Fourth Industrial Revolution, IP is a company’s most critical asset,” said Injin Hwang, the head patent attorney of Milestone IP Law Firm. “We are dedicated to supporting high-tech firms in gaining a competitive edge and achieving sustainable growth in the global marketplace.”

As the global demand for innovation rises, Milestone IP Law Firm continues to align its services with market needs. The firm has successfully supported over 100 high-tech companies, contributing to tangible growth and innovation leadership among its clients. Milestone remains committed to being the premier partner for high-tech companies, standing by their side as they lead the age of 4IR.

Media Contact
Company Name: Milestone IP Law Firm
Contact Person: Injin Hwang, Patent Attorney
Email: Send Email
Country: South Korea
Website: www.msip.kr

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Milestone IP Law Firm: Driving Global Growth for High-Tech Companies

Healthcare Analytics Market to Hit USD 133.19 Billion by 2029 with 24.3% CAGR

“The report profiles key players such as Merative (US), Optum, Inc.(US), SAS Institute Inc. (US), Oracle (US), Citiustech Inc (US), Inovalon (US), Mckesson Corporation (US), MedeAnalytics, Inc.(US), Cotiviti, Inc. (US).”

Browse 516 market data Tables and 55 Figures spread through 410 Pages and in-depth TOC on “Healthcare Analytics Market by Type (Predictive, Diagnostic), Application (Claim, RCM, Fraud, Precision Health, RWE, Imaging, Supply Chain, Workforce, Population Health), EndUser (Payer, Hospital, ACO, ASC, Govt, Clinic), & Region: Global Forecast to 2029

The global Healthcare Analytics market growth forecasted to transform from USD 44.83 billion in 2024 to USD 133.19 billion by 2029, driven by a CAGR of 24.3%. The major factors accelerating the growth of healthcare analytics market include the government initiatives to promote EHR adoption, increased venture capital investment in analytics startups, and the adoption of advanced technologies. The HITECH Act (2009), the 21st Century Cures Act (2016), and the MyHealthEData Initiative (2018) have significantly increased EHR adoption in the United States, these systems are now used by more than 90% of outpatient clinics and 95% of hospitals. Moreover, venture capital investment in AI healthcare companies will reach USD 7.2 billion in 2023, accounting for 21% of total VC healthcare investments, with USD 2.8 billion already invested in 2024 and USD 11.1 billion projected for the year.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=905

Browse in-depth TOC on “Healthcare Analytics Market”

150 – Tables

50 – Figures

350 – Pages

Based on Component, the healthcare analytics market is segmented into services and software. The services segment held the largest market share in the healthcare analytics market due to increasing need for advanced analytical methods and tools for patient monitoring and treatment outcome improvement. As patient loads and disease prevalence are increasing, massive amounts of clinical data are generated, leading to sophisticated solutions such as predictive analytics to manage and utilize this data efficiently. For instance, predictive analytics adoption rates are 66% in the United States and 79% in China. Thus, the rising demand for better patient care, cost-effective treatments, and better clinical outcomes has increased pressure on healthcare providers to implement comprehensive analytics solutions, driving the services segment’s growth.

Based on end user, the healthcare analytics market is segmented into payers, providers, pharmaceutical industry & supply chain. The provider segment dominated the healthcare analytics market due to numerous factors, such as the increasing prevalence of chronic diseases and the increasing need for improved patient care. For instance, chronic diseases are expected to account for 84% of global mortality by 2030, thus healthcare providers are increasingly using analytics to better manage and treat these conditions. Furthermore, the need to provide high-quality, cost-effective care propels providers to incorporate data analytics into their operations. Moreover, the dominance of this market segment is further enhanced by government initiatives requiring healthcare providers to maintain care standards and use resources efficiently.

Based on the region, the healthcare analytics market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The North American region dominated the healthcare analytics market because of its high healthcare spending, particularly in the US, where healthcare spending will reach 17.8% of GDP in 2021, nearly doubling the OECD average. This substantial investment has allowed healthcare providers and payers to implement advanced analytics solutions. Additionally, significant venture capital funding has fueled innovation, with USD 7.2 billion invested in AI healthcare companies in 2023 and USD 11.1 billion projected for 2024, resulting in rapid advancements in healthcare analytics technologies.

Emerging trends and technologies are poised to transform healthcare delivery and improve patient outcomes, profoundly influencing the future of healthcare analytics market. Additionally, AI-powered healthcare solutions enable personalized medicine, predictive analytics, and real-time monitoring via wearable devices and IoT sensors. These advancements allow for earlier disease detection and optimized care management, ultimately improving patient safety and satisfaction. Moreover, federated learning promotes collaborative machine learning while protecting patient privacy and encouraging data sharing between institutions. As stakeholders adopt these technological innovations, they will be able to provide proactive and equitable healthcare services to effectively address health disparities.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=905

The Healthcare analytics market is dominated by key players. The major players operating in this market are, Merative (US), Optum, Inc. (US), SAS Institute Inc. (US), Oracle (US), Citiustech Inc (US), Inovalon (US), Mckesson Corporation (US), MedeAnalytics, Inc. (US), Cotiviti, Inc. (US), Exlservice Holdings, Inc. (US), Wipro (India), Apixio. (US), Komodo Health, Inc. (US), Health Catalyst (US), CVS Health (US), Veradigm (US), Enlitic (US), HealthEC LLC (US), IQVIA (US), Arcadia Solutions, LLC. (US), Evidation Health, Inc. (US), HealthCorum (US), Aetion, Inc. (US), Tredence Inc (US), Sisense Ltd. (US).

Optum, Inc.:Optum, Inc. a part of UnitedHealth Group, is one of the top providers in healthcare analytics solutions and services market. With more than 30 years of experience, the company offers analytics managed services to support healthcare organizations, physician practices, hospitals, health systems, and health plans, enabling them to make well-informed, data-driven decisions. Their multidisciplinary team of clinical, financial, actuarial, and operational professionals uses advanced data assets and analytics technology to help clients achieve their clinical, operational, and financial objectives. The company serves its solutions and services to more than 280 healthcare payers, 5,000 hospitals, and over 100,000 healthcare facilities in the US. The company prioritizes strategic partnerships and innovations in digital health solutions to improve patient care and lower costs, particularly in value-based care and population health management.

For instance, Optum has completed its USD 7.8 billion merger with Change Healthcare (US), allowing access to data from millions of healthcare transactions and enhancing its analytics capabilities across the US population. Moreover, according to the article published by Beckers Health IT, in May 2024, Optum has spent USD 31 billion on acquisitions in the last two years. By taking these strategic moves, Optum has strengthened its position for rapid growth and increased capacity to deliver better patient care and operational effectiveness throughout the US healthcare system.

Oracle:Oracle Corporation, a global technology leader, reported USD 53 billion in revenue for fiscal year 2024. To strengthen its healthcare presence, Oracle Health paid USD 28.4 billion for Cerner in June 2022, allowing it to integrate advanced analytics and artificial intelligence (AI) into electronic health records (EHR). Oracle Health extended its EHR contract with the Veterans Affairs (VA) until 2024 and announced new collaborations aimed at improving patient care and operational efficiency through cybersecurity and interoperability initiatives. Oracle’s Health Data Warehouse is the best healthcare analytics solution, with users reporting a 417% return on investment (ROI) over five years, assist to boost the growth of company in the healthcare sector.

Merative:Merative, formerly IBM Watson Health, is a healthcare data and analytics company acquired by Francisco Partners for more than USD 1 billion in 2022; serves over 4,500 clients in the healthcare and government sectors around the world and is focused on driving growth through partnerships and acquisition. Merative’s Truven healthcare data and analytics solutions backed by 40 years of experience, serves seven of the top US health plans and more than 40% of the Fortune 500, with a client retention rate exceeding 90%, this has helped the company to enhance its value proposition, drive growth, and solidify its position in the healthcare data and analytics market.

For more information, Inquire Now!

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Healthcare Analytics Market to Hit USD 133.19 Billion by 2029 with 24.3% CAGR

HANNAH SHIN: The Fashion Brand Redefining Global Luxury with K-Pop, Innovation, and Sustainability

HANNAH SHIN, the groundbreaking fashion label from Seoul, has rapidly gained international recognition for its unique blend of glamorous sustainable fashion, K-pop culture, and cutting-edge technology. In just a few short seasons, the brand has transformed from a local favorite into a global sensation, establishing itself as a trailblazer in the fashion industry.

A Cultural Movement with K-Pop Collaborations

HANNAH SHIN has become more than just a fashion label; it’s a cultural force, thanks to collaborations with K-pop’s biggest stars, including Aespa, New Jeans, and 2NE1. The brand’s partnership with Aespa for their 2024 World Tour brought futuristic, digital-inspired designs to life, showcasing HANNAH SHIN’s commitment to innovation. Their work with New Jeans blended casual luxury with street style, captivating both K-pop fans and global fashion enthusiasts. These collaborations have elevated HANNAH SHIN’s reach and solidified its status as a trendsetter in both fashion and music.

Pioneering Fashion Innovation

Beyond celebrity collaborations, HANNAH SHIN leads in fashion innovation, partnering with KAIST and STRATASYS to integrate 3D printing (PolyJet, Large-scale FDM) and AI into its designs. At Seoul Fashion Week, the brand debuted a collection that blended cutting-edge technology with sustainable fashion, promoting “the harmonious coexistence of technology, humanity, and the environment.” This groundbreaking approach caught the attention of major international outlets like WWD, Paper Magazine, WGSN, and VOGUE, positioning HANNAH SHIN as one of the most forward-thinking brands of the season.

Expanding Global Footprint

In a stunning achievement, HANNAH SHIN has seen its export sales soar by over 10 times in just two seasons. With its collections now showcased in 12 boutiques and select shops across seven countries, including iconic fashion capitals such as New York and Paris, the brand has swiftly solidified its global presence. This rapid expansion highlights HANNAH SHIN’s growing international allure and its unique ability to seamlessly blend sustainable fashion with luxury, establishing it as a rising force in the global fashion scene.

A Future of Endless Innovation

Looking forward, all eyes are on HANNAH SHIN’s 25 FW Seoul Collection, where the brand is expected to push the boundaries of fashion even further through deeper technological collaborations. As the brand continues to explore the intersection of fashion and technology, HANNAH SHIN is not just shaping the future of fashion—it is defining a new era of sustainable luxury.

Media Contact
Company Name: HANNAH SHIN
Contact Person: Mina Shin
Email: Send Email
Country: South Korea
Website: https://www.hannah-shin.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: HANNAH SHIN: The Fashion Brand Redefining Global Luxury with K-Pop, Innovation, and Sustainability

Jenti’s Specialized LLM: Building a Safer, Smarter AI Model Beyond GPT-4

2024 marked the year of increased interest in generative AI technology, a chat-bot service based on RAG(Retrieval-Augmented Generation. These services give out answers similar to a new company recruit. They make mistakes, they do write up reports but they’ve got a long way to go. But with the proper directions, they understand and apply it well.

In August 2024, Jenti Inc. along with Hyundai Engineering developed the first plant specialized large language model(LLM). In the American PE electricity test, this model exceeded GPT-4’s performance. This is a significant result considering that the resources spent and the absolute model size is thousands smaller.

To make a well-performing domain LLM, the hard work of elite developers who can collaborate closely with comapnies while learning and optimizing data. This performance is the result of monitoring it day and night in order to maximize learning with limited GPU resources. As a result, the LLM becomes an “experienced workforce”, as experienced as a director or a manager with its sufficient learning of that field.

의류, 컴퓨터, 사람, 실내이(가) 표시된 사진

자동 생성된 설명

On-premise small LLM can gain dozens of experienced workers at once while not having to send out company assets. The large wave of generative AI has begun, and it’s time for companies to rise higher by implementing an experienced AI partner for their employees to easily use.

Media Contact
Company Name: JENTI Inc.
Contact Person: EUNJIN CHOI
Email: Send Email
Country: South Korea
Website: https://jenti.ai

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Jenti’s Specialized LLM: Building a Safer, Smarter AI Model Beyond GPT-4

Graft Versus Host Disease FDA Approvals, Clinical Trials, Pipeline Insights and Companies | DelveInsight

DelveInsight’s, “Graft versus host disease Pipeline Insight” report provides comprehensive insights about 45+ Graft Versus Host Disease Companies and 50+ pipeline drugs in Graft versus host disease pipeline landscape. It covers the Graft Versus Host Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Graft Versus Host Disease Treatment Landscape. Click here to read more @ Graft Versus Host Disease Pipeline Outlook

Key Takeaways from the Graft Versus Host Disease Pipeline Report

In January 2025:- Incyte Corporation:- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease. This study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
In January 2025: Syndax Pharmaceuticals:- This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received at least 2 prior lines of systemic therapy.
In January 2025:- Sanofi:- A Randomized, Double-blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of Belumosudil in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease (cGVHD)
DelveInsight’s Graft Versus Host Disease pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for Graft Versus Host Disease treatment.
The leading Graft Versus Host Disease Companies such as Abbisko Therapeutics, Equillium, Theriva Biologics, Seres Therapeutics, CytoMed Therapeutics, Beijing Tide Pharmaceutical Co., Ltd, CTI BioPharma, ViGenCell Inc., Lipella Pharmaceuticals, Cellestia Biotech, Jiangsu HengRui Medicine Therapeutics, Genentech, AltruBio, Orca Bio, GSK, Amgen and others.
Promising Graft Versus Host Disease Therapies such as Ibrutinib, Prednisone, ruxolitinib, Axatilimab, GDC-8264, Ruxolitinib, Defibrotide, and others.

Discover groundbreaking developments in Graft Versus Host Disease therapies! Gain in-depth knowledge of key Graft Versus Host Disease clinical trials, emerging drugs, and market opportunities @ Graft Versus Host Disease Clinical Trials Assessment

Graft versus host disease Emerging Drugs Profile

Itolizumab: Equillium

Itolizumab is a clinical-stage, first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Itolizumab was launched in India in 2013 under the brand name ALZUMAB. Itolizumab received emergency use approval in India to treat cytokine release syndrome in COVID-19 patients with moderate to severe acute respiratory distress syndrome. The drug is currently in Phase III clinical development for the treatment of acute graft-versus-host disease (aGVHD).

ABSK021: Abbisko Therapeutics

Pimicotinib (ABSK021), which was independently developed by Abbisko Therapeutics, is a novel, orally administered, highly selective and potent small-molecule inhibitor of CSF-1R. Abbisko is actively exploring the potential of pimicotinib in treating other indications including many types of solid tumors in clinic, and has obtained approval from NMPA to conduct a Phase II clinical study in chronic graft-versus-host disease. Currently, the drug is in the Phase II stage of its development for the treatment of Chronic Graft Versus Host Disease.

SYN-004: Theriva Biologics

SYN-004 (ribaxamase) is an oral prophylactic therapy designed to degrade certain IV beta-lactam antibiotics within the GI tract and maintain the natural balance of the gut microbiome for acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients. Allogeneic HCT recipients routinely receive long courses of IV beta-lactam antibiotics to treat infection. Antibiotic-mediated damage of the gut microbiome in allogeneic HCT recipients has been strongly associated with adverse outcomes including CDI, vancomycin-resistant enterococci (VRE) colonization and potentially fatal bacteremia and aGVHD. Currently, the drug is in the Phase I/II stage of its development for the treatment of Graft versus host disease.

SER-155: Seres Therapeutics

SER-155 is an oral, investigational therapeutic comprising a fermented consortium of commensal bacteria, specifically designed to support immunocompromised patients. Its primary mechanism of action involves augmenting crucial microbiome functions that contribute to improved survival and reduced risks of infections and graft versus host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). By leveraging insights from human clinical data, SER-155 aims to fortify the gut microbiome, enhance immune function, and protect against gastrointestinal infections and bacteremia. This multifaceted approach may offer a promising solution for patients facing the challenges of stem cell transplantation. Currently, the drug is in Phase I stage of its clinical trial for the treatment of GvHD.

Stay informed about the Graft Versus Host Disease pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Graft Versus Host Disease Unmet Needs

Graft Versus Host Disease Companies

Abbisko Therapeutics, Equillium, Theriva Biologics, Seres Therapeutics, CytoMed Therapeutics, Beijing Tide Pharmaceutical Co., Ltd, CTI BioPharma, ViGenCell Inc., Lipella Pharmaceuticals, Cellestia Biotech, Jiangsu HengRui Medicine Therapeutics, Genentech, AltruBio, Orca Bio, GSK, Amgen and others.

GVHD pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Graft versus host disease products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Graft versus host disease Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Transform your understanding of the Graft Versus Host Disease Pipeline! See the latest progress in drug development and clinical research @ Graft Versus Host Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Graft Versus Host Disease Pipeline Report

Coverage- Global
Graft Versus Host Disease Companies- Abbisko Therapeutics, Equillium, Theriva Biologics, Seres Therapeutics, CytoMed Therapeutics, Beijing Tide Pharmaceutical Co., Ltd, CTI BioPharma, ViGenCell Inc., Lipella Pharmaceuticals, Cellestia Biotech, Jiangsu HengRui Medicine Therapeutics, Genentech, AltruBio, Orca Bio, GSK, Amgen and others.
Graft Versus Host Disease Therapies- Ibrutinib, Prednisone, ruxolitinib, Axatilimab, GDC-8264, Ruxolitinib, Defibrotide, and others.
Graft Versus Host Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Graft Versus Host Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Immunological and Autoimmune Disorders Research–Access the Full Graft Versus Host Disease Pipeline Analysis Today! @ Graft Versus Host Disease Drugs and Companies

Table of Content

Introduction
Executive Summary
Graft versus host disease: Overview
Pipeline Therapeutics
Therapeutic Assessment
Graft versus host disease– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Itolizumab: Equillium
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
ABSK021: Abbisko Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
SER-155: Seres Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Graft versus host disease Key Companies
Graft versus host disease Key Products
Graft versus host disease- Unmet Needs
Graft versus host disease- Market Drivers and Barriers
Graft versus host disease- Future Perspectives and Conclusion
Graft versus host disease Analyst Views
Graft versus host disease Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Graft Versus Host Disease FDA Approvals, Clinical Trials, Pipeline Insights and Companies | DelveInsight

ZHIYUN Offers Big Savings on Photo and Video Gear in Chinese New Year Sale

Price reductions of up to 20% on a wide range of popular gimbals and lights

Shenzhen, China – January 28th, 2025 – In a special promotion to celebrate Chinese New Year, ZHIYUN is offering big savings of up to 20% on professional photography and video-making gear. There are limited-time offers on ZHIYUN’s popular camera and smartphone stabilization systems, and portable lighting, including best-selling models from the Crane, WEEBILL and FIVERAY series. The promotion runs from January 27 to February 9, 2025, and products are available from ZHIYUN’s official store and ZHIYUN’s Amazon store.

Gimbals for professional-quality video and photos

During the sale, buyers can save 17% on the Crane M3S compact, portable gimbal, with prices starting from $249. This 705g (1.5 lbs) stabilizer has an impressive load-bearing capacity to handle a wide range of mainstream full-frame cameras and lens combos. It can also be used with mobile phones, mirrorless cameras, and action cameras. The Crane M3S Combo, with extra accessories, is available for only $299. For details: geni.us/pr-CRANEM3S.

ZHIYUN’s WEEBILL 3E lightweight gimbal with enhanced stabilization is available for just $211, a 15% reduction. The WEEBILL 3E breaks new ground with its innovative design and powerful performance, offering a compelling solution for filmmakers, videographers, and content creators who need a lightweight, versatile, and user-friendly gimbal. Find out more at: geni.us/pr-WB3E.

Compact pocket-sized lights

The FIVERAY M20 and M20C pocket-sized 20W lights combine professional-level features with consumer-level ease-of-use in an easily portable format – promotion prices start from $65 for the M20 and $109 for the M20C. Weighing just 200g (7 oz), these devices offer videographers and photographers a powerful light in a compact, portable form factor. The M20 has a wide, adjustable color range, and the full-RGB M20C offers completely controllable lighting and color rendering. Price reductions of up to 19% are available on the M20, M20C and Combo packages with additional accessories. Purchase the M20 at geni.us/pr-M20 and find the M20C at geni.us/pr-M20C.

ZHIYUN’s FIVERAY M40 light provides 40W of high power lighting in a lightweight palm-sized device that fits in a pocket. It provides stable illuminance of up to 14,000 lux with adjustable color temperature from 2,700K-6,200K. It is reduced by 15%, to $84, during the new year promotion. Discover the M40 at: geni.us/pr-M40.

The CINEPEER CM25 pocket-sized 25W fill light offer simple but high-performance lighting. During the sale, it is even more affordable at just $49. Weighing only 232g, the CM25 can achieve a professional luminous efficacy of 3360 Lux, with accurate color rendering. Find out more at: geni.us/pr-CM25

Versatile 100 watt lights

Unlike traditional 100W lights, ZHIYUN’s CINEPEER CX100 is ultra-lightweight at just 710g (about 1.5 lbs), and small enough to fit in the hand. The large dial controls make color and brightness adjustments intuitive. The CX100 is reduced by 20% to $143. Purchase at: geni.us/pr-CX100

ZHIYUN’s CINEPEER CF100 100W stick light supports both HSI and RGB modes. It provides almost twice the full-color output performance of competing products, enabling effective background illumination and vibrant color scene capture. This lightweight device is available for $152 during the new year promotion. Find out more at: geni.us/pr-CF100.

Promotion period: January 27 – February 9, 2025

Amazon Store Link: geni.us/AMZ-Store-PR-Sales

ZHIYUN Official Store Link: geni.us/ZHIYUN-Store-PR

About ZHIYUN

ZHIYUN Tech is a pioneer and a world-leader in gimbals and stabilizers and provides exceptional film lighting solutions for everyone from professional filmmakers to amateur video creators. ZHIYUN believes in “MAKE IT REAL”: a commitment to arduous research and development to create breakthroughs in technological and industrial innovations. ZHIYUN’s standout products and features deliver everyday convenience, better experiences, and unlock new opportunities to make the imagination a reality.

Learn more about ZHIYUN Tech at www.ZHIYUN-tech.com or check them out on Facebook: @Zhiyun-Tech or follow them on Instagram: @ZHIYUN_Tech

Media Contact
Company Name: Guilin Zhishen Information Technology Co., Ltd.
Contact Person: Mei Chang
Email: Send Email
Phone: +86 400 900 6868
City: Shenzhen
Country: China
Website: https://www.zhiyun-tech.com/en

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: ZHIYUN Offers Big Savings on Photo and Video Gear in Chinese New Year Sale

Gene Editing Market to Hit USD 7.59 Billion by 2029 with 10.2% CAGR

“Key players in the gene editing market are Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), GenScript (US), Agilent Technologies, Inc. (US), Revvity (US), Lonza (US), Tecan Trading AG (Switzerland)”

Browse 636 market data Tables and 65 Figures spread through 497 Pages and in-depth TOC on “Gene Editing Market by Product (Kits, Reagents, Libraries, Software), Services (gRNA Synthesis & Vector Construction), Technique (Knock-Out, Knock-In), Technology (CRISPR, ZFN, TALEN), Application (Genome Editing, Drug Discovery) – Global Forecast to 2029

The global gene editing market is expected to reach USD 7.59 billion in 2029 from USD 4.66 billion in 2024, at a CAGR of 10.2% during the forecast period. The main factors behind the expansion of this market are demand for personalized medicine, and favourable government funding investments for gene editing projects. The expanding range of gene editing applications, spurred by technological advancements in prime editing, bridge RNA and the growing burden of congenital diseases, are also contributing to the market’s expansion.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231037000

Browse in-depth TOC on “Gene Editing Market“

636 – Tables

65 – Figures

497 – Pages

Based on Offerings, the market is divided into products and services segments. The products segment accounted for the largest share of the gene editing market in 2023. The large share of products is majorly due to the reagents, kits, and other consumables that are used in CRISPR, TALEN, ZFN and other gene editing technologies for applications such as cell line development, drug discovery and development and genome engineering represent a major product category, contributing to a large market share. However, the service segment accounted for the second-largest share in the market.

Based on Product Type, the market is divided into reagents & consumables, and Software & systems. The reagents & consumables segment held the highest share of the market in 2023. Reagents & consumables consists of gene editing kits, gene editing reagents, and gene editing libraries all of which are essential into carry out gene editing experiments and workflow. Gene editing reagents & consumables encompass various essential components, such as nucleases, controls, antibodies and enzymes, that support the gene editing process and cater to diverse applications, including cell line engineering, genome editing, drug discovery and development. However, software & systems held the second highest share.

Based on Reagents & Consumables Technique, the market is segmented into knock-out, knock-in, gene silencing and other techniques which include jump-in, homologous recombination, gene overexpression among others. The reagents, kits, and consumables segment accounted for the largest share of the genomics market in 2023. Reagents, kits, and other consumables used in sequencing, PCR, and microarray technologies represent a major product category, contributing to a large market share. However, the instrument segment accounted for the second largest share in the segment. The knock-out segment held the highest share owing to large applications in gene editing process like drug discovery and cell line engineering, however knock-in held the second highest share of the gene editing reagents & consumables market by technique.

Based on Product Technology, the gene editing market is segmented into CRISPR, TALEN, ZFN, Base editing, Antisense, RNAi and other technologies which include PiggyBac, Prime editing among others. The CRISPR segment held the highest share of the gene editing products market by technology driven by advancements in CRISPR technology, products cater to a range of CRISPR applications, from gene knockout to precise gene correction or insertions using tools like donor oligos and design software for CRISPR-based genome editing. However, TALEN held the second highest share of the gene editing market.

Based on Product Application, the gene editing market is segmented into cell line engineering, genome editing/genetic engineering, drug discovery and development and other applications which include clinical diagnostics, xenotransplantation among others. The cell line engineering segment held the highest share of the market owing to increase in demand for precise cell line engineering and development for research and development purposes. Products are utilized in cell line engineering to facilitate precise genetic modifications and supporting various research applications. Key products in this market include reagents & Kits, Software and Systems which are utilized for gene knockouts, knock-ins, and point mutations in cell line. However, genome editing/genetic engineering held the second highest share of the gene editing products market by application.

Based on Product End User, the gene editing market is segmented into Pharmaceutical & biotechnology companies, academic & research institutes, CROs & CDMOs and other end users which include clinical diagnostic companies, biobanks among others. Pharmaceutical & biotechnology companies held the highest share of the market owing to high demand for gene editing products in R&D and drug development departments of these companies. Gene editing products are indispensable for advancing gene-based therapies, making them critical for pharmaceutical & biotechnology companies aiming to innovate in areas like oncology, rare diseases, and immunology. Academic & research institutes held the second highest share of the gene editing products market by end user due to increase demand for gene editing products in research and experimentation involving gene editing.

Based on Service Type, the gene editing market is segmented into cell line development & engineering, gRNA synthesis and vector construction, Library construction & screening, and other services which include off-target analysis and mutagenesis services. Cell line development & engineering held the highest share of the market. The gene editing services in cell line development and engineering are utilized for precise genome modifications for research, drug discovery, and biopharmaceutical production. Services utilize several gene editing technologies such as CRISPR which allow for knockouts, knock-ins, and targeted mutations across a wide variety of mammalian and other cell types. gRNA synthesis & vector construction held the second highest share of the market. The ability to customize vectors, including options for fluorescent or resistance gene markers, enriches the transfected cells, improving gene editing efficiency which is driving growth in this market.

Based on Service Application, the gene editing market is segmented into cell line engineering, genome editing/genetic engineering, drug discovery & development and other applications which include clinical diagnostics, and xenotransplantation among others. The drug discovery & development application held the highest share of the gene editing services market by application in 2023. The drug discovery & development segment is further sub segmented into blood disorders, cancer, CNS and others which include Ophthalmology, infections and dystrophies among others. The rising trend of companies exploring and developing gene therapies for these disorders is driving the demand for gene editing services in drug discovery and development. Cell line engineering application held the second highest share of the market.

Based on Service End User, the gene editing market is segmented into pharmaceutical & biotechnology companies, Academic & research institutes, and other end users which include diagnostic companies, biobanks, and small-scale CDMOs among others. Pharmaceutical & biotechnology companies held the highest share of the market as they utilize various types of services such as cell line development and engineering, gRNA synthesis & vector construction, and Library construction and screening for various applications such as drug discovery and development. However Academic and research institutes held the second highest share of the gene editing services by end user.

The gene editing market is segmented into six major regions, namely, North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America is the largest regional market for gene editing in 2023, while Europe is the second-largest market. The large share of North America can be attributed to the surge in development and approval of advanced therapies requiring gene editing products and services. However, The Asia Pacific is estimated to be the fastest-growing segment of the market characterized by a significant focus on R&D activities to broaden the scope of genomics applications, increasing adoption of genomics technologies for diagnostics, and technological developments in genomic data analysis.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=231037000

The gene editing market is competitive with key players such Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), GenScript (US), Agilent Technologies, Inc. (US), Revvity (US). The market players have adopted various strategies such as development of advanced products, services, partnerships, contracts, expansions, and acquisitions to strengthen their position in the gene editing market. The organic and inorganic strategies have helped the market players expand globally by providing advanced gene editing products and services.

Thermo Fisher Scientific Inc. (US):

Thermo Fisher Scientific Inc. provides an extensive portfolio of life science solutions, analytical instruments, diagnostics, and laboratory services for many applications. The company offers a comprehensive portfolio of gene editing products and services, encompassing tools, services, and software for gene modification. The company provides gene editing tools and services via the Genetic Sciences and Biosciences business within the life sciences solutions segment. The company has executed organic and inorganic growth strategies, launching products such as the Gibco CTS AAV-MAX Helper-Free AAV Production System in November 2022, establishing a manufacturing facility at the University of California, San Francisco in March 2023, and acquiring gene editing companies like PeproTech, Inc. (US) in January 2022.

Merck KGaA (Germany):

Merck KGaA is a healthcare-focused research and technology company. The company offers gene editing technologies and services through the Science & Lab Solutions subsegment of the Life Sciences segment. Sigma Aldrich and Milliporesigma are the brand names under which the firm distributes its gene editing solutions. The firm has a global reach through its subsidiaries and brands. The company expanded inorganically by acquiring Mirus Bio, Inc. (US) in May 2024 and forming a partnership with Synplogen Co., Ltd. (Japan) in December 2022.

GenScript (US):

Genscript is a biotechnology company that provides life science research application instruments and services. The company operates in the gene editing market through the Life Science Services and Products segment which provides comprehensive life-science research services and products. The company operates in over 100 countries through various subsidiaries. GenScript (US) pursued organic growth with the launch of FLASH Gene in June 2024 and expansion of gene synthesis services in Singapore in February 2023, while also forming an inorganic partnership with PersonGen-Anke Cellular Therapeutics (US) in March 2023 to enhance cell therapy development.

Agilent Technologies, Inc. (US):

Agilent Technologies, Inc. is a life sciences, diagnostics, and applied chemicals company that offers instruments, software, consumables and services for entire laboratory workflow. The company offers gene editing products and services through the diagnostics and genomics business segment. The company has several subsidiaries spanning across all major regions. The company strengthened inorganically by acquiring BIOVECTRA, Inc. (Canada) in July 2024 and collaborating with Merck KGaA (Germany) in June 2022 to advance process technologies and organically by expansion of a manufacturing facility in China in August 2021.

Revvity (US):

Revvity is a health science solutions company that focuses on technology and services ranging from research to development and diagnosis. Revvity provides a variety of products and services in the Life Sciences segment, including gene editing products and services, to help with cell, gene, and protein studies. Revvity distributes its products and services in over 160 countries. Revvity pursued organic growth by launching its pin-point base editing platform reagents in September 2023, while inorganic growth was achieved through collaborations with GenKOre (South Korea) in June 2023 and a partnership with AstraZeneca Plc (UK) in May 2023, which involved licensing their services to develop advanced gene therapies.

For more information, Inquire Now!

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gene Editing Market to Hit USD 7.59 Billion by 2029 with 10.2% CAGR